Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873521 | 0.85 | ALDH1A1 (0.45) | NQO2ALDH1A1CYP3A4KMT2AOPRK1 | |
| SCHEMBL5752521 | 0.85 | NQO2 (0.48) | NQO2ALDH1A1CYP3A4KMT2AOPRK1 | |
| SCHEMBL5752032 | 0.79 | KMT2A (0.41) | ALDH1A1KMT2AOPRK1LCKMEN1 | |
| SCHEMBL17884009 | 0.74 | AMY1A (0.33) | AMY1A | |
| SCHEMBL5754517 | 0.74 | KMT2A (0.38) | ALDH1A1KMT2AOPRK1MEN1 | |
| SCHEMBL25330902 | 0.73 | ALDH1A1 (0.35) | ALDH1A1CYP3A4KMT2AOPRK1MEN1 | |
| SCHEMBL5756956 | 0.72 | NQO2 (0.50) | NQO2ALDH1A1CYP3A4KMT2AGLA | |
| SCHEMBL17884020 | 0.71 | — | — | |
| SCHEMBL31283877 | 0.71 | — | — | |
| SCHEMBL30634862 | 0.71 | PRNP (0.38) | NQO2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354656-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2017-12-14 | — | — | US | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| WO-2016105564-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-1218358-B1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1218358-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-6399603-B1 | QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY | ASTRAZENECA AB (SE) | 2002-06-04 | — | — | US | disclosed |
| WO-2001021598-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | TTBK1, TTBK2, MAPT | NQO2 13/4885ALDH1A1 2216/4885CYP3A4 15/4885 |
| US-20170354656-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | NQO2 13/4885ALDH1A1 2216/4885CYP3A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.